PHVS
Pharvaris N.V.
$31.59
+1.61%
$2.2B
No data for this timeframe.
Vol
Market Cap$2.2B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (90%)
Insider Activity0B / 23S
Insider Net $-$4.6M
SEC Reports17
Press Releases6
Recent Activity
Jun 5, 2026
short_volume
Short Volume: PHVS — 85.5% short (0.4M / 0.5M)
Short: 429,773 | Exempt: 0 | TRF Vol: 502,828 | Short Ratio: 85.5% | Off-exchange volume (dark pool
Jun 4, 2026
Insider
Nijdam Anna sold 2,670 shares
Principal Accounting Officer @ $30.87 ($82.4K)
May 29, 2026
Press
Pharvaris announced the acceptance of 8 abstracts (1 oral, 7 flash talk/poster) at the EAACI 2026 congress, including Ph
Impact 4/10
May 26, 2026
SEC
A cluster of 8 Pharvaris insiders, including the CEO, CFO, and CCO, sold a total of $1.73M in open-market sales over a 7
CLUSTER — Impact 4/10
May 26, 2026
SEC
Six Pharvaris insiders, including the CEO, CFO, and CCO, sold a total of $1.38M in stock over a 7-day window. The cluste
CLUSTER — Impact 5/10
May 22, 2026
SEC
Five Pharvaris insiders, including the CEO and CCO, sold a total of ~$1.08M in open-market sales over a 7-day window, fo
CLUSTER — Impact 3/10
May 22, 2026
Insider
Nijdam Anna sold 5,501 shares
Principal Accounting Officer @ $30.74 ($169.1K)
May 22, 2026
Insider
Nijdam Anna sold 5,501 shares
Principal Accounting Officer @ $20.00 ($110.0K)
Price Targets
$46.26
+46.4% upside
Strong Buy
Current $31.60
Low $32.57
Median $41.50
High $72.93
13 analysts
$32.57
$72.93
Analyst Ratings
9Strong Buy
9Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Apr 9, 2026 | Wolfe Research | INITIATE | Outperform |
| Apr 7, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Apr 6, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| Mar 9, 2026 | RBC Capital | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.65 ▲ +12.3% | $-0.70 — $-0.59 | 21% YoY | 10 |
| Next Q | $-0.66 ▲ +11.8% | $-0.72 — $-0.61 | -11% YoY | 10 |
| Current FY | $-2.64 ▲ +9.0% | $-2.96 — $-2.17 | 11% YoY | 12 |
| Next FY | $-2.35 ▲ +10.1% | $-3.29 — $-1.41 | 11% YoY | 12 |
Latest Reports
NEUTRAL
Press
4/10
Pharvaris announced the acceptance of 8 abstracts (1 oral, 7 flash talk/poster) at the EAACI 2026 congress, including Ph
May 29, 2026
NEUTRAL
CLUSTER
4/10
A cluster of 8 Pharvaris insiders, including the CEO, CFO, and CCO, sold a total of $1.73M in open-market sales over a 7
May 26, 2026
BEARISH
CLUSTER
5/10
Six Pharvaris insiders, including the CEO, CFO, and CCO, sold a total of $1.38M in stock over a 7-day window. The cluste
May 26, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Nijdam Anna | SELL | $82.4K |
| May 22, 2026 | Nijdam Anna | SELL | $169.1K |
| May 22, 2026 | Nijdam Anna | M | $110.0K |
| May 22, 2026 | Nijdam Anna | M | $0.00 |
| May 21, 2026 | Nassif David | SELL | $303.1K |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
11 unique insiders with 23 transactions. Net insider value: -$4.6M ($0.00 bought, $4.6M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Nijdam Anna | Principal Accounting Officer | SELL | 2,670 | $30.87 | $82.4K |
| May 22, 2026 | Nijdam Anna | Principal Accounting Officer | SELL | 5,501 | $30.74 | $169.1K |
| May 22, 2026 | Nijdam Anna | Principal Accounting Officer | M | 5,501 | $20.00 | $110.0K |
| May 22, 2026 | Nijdam Anna | Principal Accounting Officer | M | 5,501 | $0.00 | $0.00 |
| May 21, 2026 | Nassif David W. | CFO / CLO | SELL | 10,000 | $30.31 | $303.1K |
| May 21, 2026 | Nijdam Anna | Principal Accounting Officer | M | 1,829 | $20.00 | $36.6K |
| May 21, 2026 | Nijdam Anna | Principal Accounting Officer | SELL | 1,829 | $30.60 | $56.0K |
| May 21, 2026 | Nijdam Anna | Principal Accounting Officer | M | 1,829 | $0.00 | $0.00 |
| May 21, 2026 | Monges Viviane | Director | SELL | 9,667 | $30.29 | $292.9K |
| May 20, 2026 | Bjork Elisabeth | Director | M | 10,000 | $8.05 | $80.5K |
| May 20, 2026 | Bjork Elisabeth | Director | SELL | 10,000 | $29.32 | $293.2K |
| May 20, 2026 | Bjork Elisabeth | Director | M | 10,000 | $0.00 | $0.00 |
| May 18, 2026 | Modig Berndt | Chief Executive Officer | SELL | 2,292 | $29.22 | $67.0K |
| May 15, 2026 | Abele Stefan Andreas | Chief Technical Ops Officer | SELL | 8,748 | $29.82 | $260.9K |
| May 15, 2026 | Souverijns Wim | Chief Commercial Officer | SELL | 10,000 | $29.92 | $299.2K |
| May 15, 2026 | Glassman Robert | Director | M | 5,333 | $22.31 | $119.0K |
| May 15, 2026 | Glassman Robert | Director | SELL | 5,333 | $29.83 | $159.1K |
| May 15, 2026 | Glassman Robert | Director | M | 5,333 | $0.00 | $0.00 |
| May 12, 2026 | Lu Peng | Chief Medical Officer | F | 117 | $29.95 | $3.5K |
| May 11, 2026 | Lu Peng | Chief Medical Officer | F | 109 | $30.09 | $3.3K |
| May 1, 2026 | Lu Peng | Chief Medical Officer | M | 14,023 | $0.00 | $0.00 |
| May 1, 2026 | Lu Peng | Chief Medical Officer | M | 14,166 | $2.59 | $36.7K |
| May 1, 2026 | Lu Peng | Chief Medical Officer | SELL | 14,023 | $30.16 | $423.0K |
| Apr 30, 2026 | Lu Peng | Chief Medical Officer | M | 15,000 | $2.59 | $38.9K |
| Apr 30, 2026 | Lu Peng | Chief Medical Officer | SELL | 15,000 | $30.24 | $453.6K |
| Apr 30, 2026 | Lu Peng | Chief Medical Officer | M | 15,000 | $0.00 | $0.00 |
| Apr 30, 2026 | Lesage Anne | Chief Early Development | M | 3,700 | $2.59 | $9.6K |
| Apr 30, 2026 | Lesage Anne | Chief Early Development | SELL | 3,700 | $30.26 | $111.9K |
| Apr 30, 2026 | Lesage Anne | Chief Early Development | M | 3,700 | $0.00 | $0.00 |
| Apr 30, 2026 | Schikan Johannes Gerardus Christiaan Petrus | Director | SELL | 28,400 | $30.30 | $860.6K |
| Apr 29, 2026 | Lu Peng | Chief Medical Officer | M | 3,733 | $2.59 | $9.7K |
| Apr 29, 2026 | Lu Peng | Chief Medical Officer | SELL | 3,733 | $30.06 | $112.2K |
| Apr 29, 2026 | Lu Peng | Chief Medical Officer | M | 3,733 | $0.00 | $0.00 |
| Apr 29, 2026 | Lesage Anne | Chief Early Development | M | 3,700 | $2.59 | $9.6K |
| Apr 29, 2026 | Lesage Anne | Chief Early Development | SELL | 3,700 | $30.08 | $111.3K |
| Apr 29, 2026 | Schikan Johannes Gerardus Christiaan Petrus | Director | SELL | 3,830 | $30.07 | $115.2K |
| Apr 29, 2026 | Lesage Anne | Chief Early Development | M | 3,700 | $0.00 | $0.00 |
| Apr 23, 2026 | Schikan Johannes Gerardus Christiaan Petrus | Director | SELL | 100 | $30.03 | $3.0K |
| Apr 23, 2026 | Lu Peng | Chief Medical Officer | M | 100 | $2.59 | $259.00 |
| Apr 23, 2026 | Lu Peng | Chief Medical Officer | SELL | 100 | $30.03 | $3.0K |
| Apr 23, 2026 | Lu Peng | Chief Medical Officer | M | 100 | $0.00 | $0.00 |
| Apr 23, 2026 | Lesage Anne | Chief Early Development | M | 100 | $0.00 | $0.00 |
| Apr 23, 2026 | Lesage Anne | Chief Early Development | SELL | 100 | $30.03 | $3.0K |
| Apr 23, 2026 | Lesage Anne | Chief Early Development | M | 100 | $2.59 | $259.00 |
| Apr 22, 2026 | Schikan Johannes Gerardus Christiaan Petrus | Director | SELL | 7,000 | $30.05 | $210.4K |
| Apr 22, 2026 | Lu Peng | Chief Medical Officer | M | 7,001 | $2.59 | $18.1K |
| Apr 22, 2026 | Lu Peng | Chief Medical Officer | SELL | 7,001 | $30.05 | $210.4K |
| Apr 22, 2026 | Lu Peng | Chief Medical Officer | M | 7,001 | $0.00 | $0.00 |
| Apr 22, 2026 | Lesage Anne | Chief Early Development | M | 500 | $2.59 | $1.3K |
| Apr 22, 2026 | Lesage Anne | Chief Early Development | SELL | 500 | $30.00 | $15.0K |
17 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 1 mixed, 14 neutral. Avg impact: 3.8/10.
NEUTRAL
CLUSTER
4/10
A cluster of 8 Pharvaris insiders, including the CEO, CFO, and CCO, sold a total of $1.73M in open-m
May 26, 2026
BEARISH
CLUSTER
5/10
Six Pharvaris insiders, including the CEO, CFO, and CCO, sold a total of $1.38M in stock over a 7-da
May 26, 2026
NEUTRAL
CLUSTER
3/10
Five Pharvaris insiders, including the CEO and CCO, sold a total of ~$1.08M in open-market sales ove
May 22, 2026
NEUTRAL
144
3/10
Director David W. Nassif filed a Form 144 notice of intent to sell 10,000 common shares of Pharvaris
May 21, 2026
NEUTRAL
CLUSTER
3/10
Four insiders at Pharvaris, including the CEO and Chief Commercial Officer, sold shares totaling $78
May 20, 2026
NEUTRAL
144
2/10
Form 144: Director Elisabeth Bjork intends to sell 10,000 PHVS shares (~$293K) via a cashless stock
May 20, 2026
NEUTRAL
CLUSTER
4/10
Two C-suite insiders at Pharvaris sold a combined $560K in open-market sales on May 15, 2026, just 1
May 19, 2026
NEUTRAL
PRESS-RELEASE
5/10
Pharvaris reported Q1 2026 EPS of €-0.59 (IFRS), a narrower loss vs €-0.85 a year ago, with cash of
May 12, 2026
NEUTRAL
6-K
4/10
Pharvaris closed an underwritten public offering of 4,455,863 ordinary shares at $29.68 per share, r
May 11, 2026
NEUTRAL
424B5
4/10
Pharvaris filed a prospectus supplement for an underwritten public offering of 3,874,664 ordinary sh
May 8, 2026
NEUTRAL
CLUSTER
4/10
Three Pharvaris insiders (CMO, Chief Early Development, Director) sold a combined ~$2.19M in open-ma
May 5, 2026
NEUTRAL
CLUSTER
2/10
Three Pharvaris insiders sold a total of $118K in stock over a one-week window, with the Chief Medic
May 1, 2026
BEARISH
CLUSTER
5/10
Four corporate insiders at Pharvaris N.V. (PHVS) sold shares in a concentrated 7-day window, includi
Apr 24, 2026
NEUTRAL
CLUSTER
3/10
Two C-suite executives at Pharvaris sold shares in the past week, including CEO Modig Berndt and CMO
Apr 24, 2026
NEUTRAL
144
3/10
Berndt Modig, a director and officer of Pharvaris N.V., filed a Form 144 to notify of intent to sell
Apr 8, 2026
MIXED
6-K
6/10
Pharvaris reported its 2025 financial results and provided updates on its clinical development pipel
Apr 2, 2026
NEUTRAL
PRESS-RELEASE
4/10
Pharvaris reported a narrow EPS beat of 3% ($-0.60 vs $-0.62 consensus) with no revenue, typical for
Apr 2, 2026
NEUTRAL
4/10
Pharvaris announced the acceptance of 8 abstracts (1 oral, 7 flash talk/poster) at the EAACI 2026 co
May 29, 2026
NEUTRAL
5/10
Pharvaris closed a $132.3M underwritten offering of 4.46M ordinary shares, including full exercise o
May 11, 2026
BEARISH
6/10
Pharvaris priced a $115M underwritten offering of 3.87M shares at $29.68 per share, representing ~6%
May 8, 2026
BULLISH
8/10
Pharvaris announced the publication of positive Phase 2 data from its CHAPTER-1 and RAPIDe-1 trials
Mar 20, 2026
NEUTRAL
4/10
Pharvaris announced the publication of a real-world study validating patient-reported outcome measur
Mar 11, 2026
BULLISH
8/10
Pharvaris presented positive Phase 3 RAPIDe-3 and long-term CHAPTER-1 trial data for deucrictibant,
Mar 2, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 20 analysts: 9 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$46.26 mean target
+46.4% upside
Strong Buy (1.38)
$32.57 Low
$72.93 High
| Metric | Value |
|---|---|
| Current Price | $31.60 |
| Target Low | $32.57 |
| Target Mean | $46.26 |
| Target Median | $41.50 |
| Target High | $72.93 |
| # Analysts | 13 |
| Recommendation | Strong Buy (1.38) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.65 | $-0.70 | $-0.59 | 21.4% | +12.3% | 6↑ 1↓ | $0.0B | 0.0% | 10 |
| Next Q 2026-09-30 |
$-0.66 | $-0.72 | $-0.61 | -10.7% | +11.8% | 6↑ 1↓ | $0.0B | 0.0% | 10 |
| Current FY 2026-12-31 |
$-2.64 | $-2.96 | $-2.17 | 11.1% | +9.0% | 8↑ 1↓ | $0.0B | 0.0% | 12 |
| Next FY 2027-12-31 |
$-2.35 | $-3.29 | $-1.41 | 11.0% | +10.1% | 4↑ 4↓ | $0.0B | 0.0% | 12 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.653 | |
| 7d ago | $-0.653 | |
| 30d ago | $-0.744 | +0.092 |
| 60d ago | $-0.735 | +0.082 |
| 90d ago | $-0.669 | +0.017 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Apr 9, 2026 | Wolfe Research | INITIATE | — | Outperform |
| Apr 7, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Apr 6, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Mar 9, 2026 | RBC Capital | INITIATE | — | Outperform |
| Mar 3, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 9 | 9 | 2 | 0 | 0 | 90% | |
| May 1, 2026 | 9 | 9 | 2 | 0 | 0 | 90% | |
| Apr 1, 2026 | 8 | 8 | 3 | 0 | 0 | 84% | |
| Mar 1, 2026 | 8 | 8 | 2 | 0 | 0 | 89% | |
| Feb 1, 2026 | 8 | 8 | 2 | 0 | 0 | 89% | |
| Jan 1, 2026 | 8 | 8 | 2 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 5, 2026
short_volume
Short Volume: PHVS — 85.5% short (0.4M / 0.5M)
Short: 429,773 | Exempt: 0 | TRF Vol: 502,828 | Short Ratio: 85.5% | Off-exchange volume (dark pool + OTC)
May 29, 2026
m_and_a
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
<p>ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=uIICqmiceZmFaQX1lirebCTPG7oe4vBjVy6xsIVLfD
May 13, 2026
earnings_calendar
PHVS Q1 2026 Earnings After Market Close — 2026-05-13
May 12, 2026
earnings
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
<p>ZUG, Switzerland, May 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ap0VDnQ7jDO_yY7UvMxNgiKgXwMZS6xN40V_VvUN4i
May 11, 2026
Clinical Trial
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Phase Phase 3 — ACTIVE_NOT_RECRUITING
May 11, 2026
clinical_trial_readout
T-90d Trial Readout: Deucrictibant (Phase 3)
Trial: Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Sponsor: Phar
May 11, 2026
m_and_a
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
<p>ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing
May 11, 2026
earnings_calendar
PHVS Q1 2026 Earnings After Market Close — 2026-05-11
May 8, 2026
m_and_a
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
<p align="left">ZUG, Switzerland, May 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical compan
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: Deucrictibant (Phase 3)
Trial: Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Sponsor: Phar
May 3, 2026
clinical_trial_readout
T-90d Trial Readout: Deucrictibant (Phase 3)
Trial: Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Sponsor: Phar
Apr 20, 2026
fda
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
<p align="left">ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=6Z-xvZ5cSjSzN4MRb7H1XlgmGAS
Apr 2, 2026
earnings
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
<p>ZUG, Switzerland, April 02, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=SNAbJG7PsfRppECSVkhz-n5P1v70ibM7L8Ndmn2X
Apr 2, 2026
earnings_result
PHVS Q4 2025 Earnings: EPS $-0.72 (-13.7% vs est)
Mar 20, 2026
m_and_a
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
<p>ZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=tCrM0HjLiGqebw91VaAfFyF8jJnAoihy1v6AdJ8b
Mar 11, 2026
fda
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
<p>ZUG, Switzerland, March 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=8Dt544f3n5hCEAS00t4WCXd1eMSO1caJcn4suJVN